Characteristics of human NK clones: target specificity and phenotype
- PMID: 6201541
Characteristics of human NK clones: target specificity and phenotype
Abstract
Clones derived from purified human large granular lymphocytes (LGL) of three different donors were expanded in culture medium supplemented with interleukin 2 (IL 2). Their cytotoxic activity was tested in a 51Cr-release cytotoxicity assay against a panel of three to five NK-susceptible tumor cell lines. Of 196 LGL clones tested, only 44 (22.4%) displayed significant cytotoxic activity. A heterogeneous pattern of reactivity was seen; 26 clones (59%) killed all the targets within the panel tested, whereas 18 clones (41%) had a more restricted specificity. Among these 18 clones, 12 lysed only one target (K562, six clones; ADCC, three clones; Daudi, two clones; MOLT-4, one clone), whereas the other six killed two different targets (ADCC and A1ab, one clone; K562 and MOLT-4, five clones). Clones derived from LGL preselected for positive reactivity with the monoclonal antibodies (MoAb) alpha OKM1, alpha OKT10 and alpha B73.1 also demonstrated either broad or restricted patterns of cytotoxicity. The LGL reactive with MoAb alpha B73.1 gave a high percentage of cytotoxic clones. Phenotype analysis showed that clones could express both antigens associated with T cells (i.e., OKT3, OKT4, and OKT8) and antigens shared by LGL (i.e., OKM1, OKT10, and B73.1). The pattern of surface markers varied considerably among the clones; however, no clear correlation between the pattern of antigenic phenotype and cytotoxic activity was seen. These data show that clones derives from purified preparations of LGL present different functional and antigenic characteristics, and support the hypothesis that the heterogeneity of the entire NK population is attributable, at least in part, to a mixture of clones that vary substantially in their target specificities and phenotypes.
Similar articles
-
Specificity and phenotype of IL-2 expanded clones of human large granular lymphocytes.Diagn Immunol. 1983;1(3):162-7. Diagn Immunol. 1983. PMID: 6209054
-
Rapidly expanded activated human killer cell clones have strong antitumor cell activity and have the surface phenotype of either T gamma, T-non-gamma, or null cells.J Immunol. 1984 Jun;132(6):3185-91. J Immunol. 1984. PMID: 6233369
-
Characterization of human large granular lymphocyte subpopulations: comparison of the phenotype of NK cells and of interleukin 2-dependent progenitors of cytolytic effector cells.Nat Immun Cell Growth Regul. 1985;4(1):7-20. Nat Immun Cell Growth Regul. 1985. PMID: 3875792
-
A clonal analysis of human peripheral blood lymphocytes displaying natural killer-like activity.Eur J Immunol. 1985 May;15(5):448-56. doi: 10.1002/eji.1830150507. Eur J Immunol. 1985. PMID: 3873338
-
Continuous cytotoxic T-cell lines.Contemp Top Immunobiol. 1980;11:139-55. doi: 10.1007/978-1-4684-3701-0_4. Contemp Top Immunobiol. 1980. PMID: 7004767 Review. No abstract available.
Cited by
-
T-cell receptor beta gene rearrangements in clones derived from human CD4-8- cells expressing natural killer cell activity.Immunology. 1988 Dec;65(4):597-604. Immunology. 1988. PMID: 2851542 Free PMC article.
-
Human thymic and peripheral blood non-MHC-restricted cytotoxic lymphocytes.Med Oncol Tumor Pharmacother. 1986;3(3-4):247-54. doi: 10.1007/BF02935001. Med Oncol Tumor Pharmacother. 1986. PMID: 2433552 Review.
-
Mechanism of target cell recognition by natural killer cells: characterization of a novel triggering molecule restricted to CD3- large granular lymphocytes.J Exp Med. 1991 Dec 1;174(6):1527-36. doi: 10.1084/jem.174.6.1527. J Exp Med. 1991. PMID: 1720812 Free PMC article.
-
Natural cytotoxicity in the neonate: high levels of lymphokine activated killer (LAK) activity.Clin Exp Immunol. 1988 Jan;71(1):177-81. Clin Exp Immunol. 1988. PMID: 2964956 Free PMC article.
-
Coexpression of Fc gamma receptor IIIA and interleukin-2 receptor beta chain by a subset of human CD3+/CD8+/CD11b+ lymphocytes.J Clin Immunol. 1993 May;13(3):228-36. doi: 10.1007/BF00919976. J Clin Immunol. 1993. PMID: 7686565